Sofosbuvir / Velpatasvir / Voxilaprevir

Rosuvastatin

Contraindicated.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Sofosbuvir / Velpatasvir / Voxilaprevir may inhibit hepatic transports OATP1B1 and BCRP and increase plasma concentration of Rosuvastatin.

Sofosbuvir / Velpatasvir / Voxilaprevir

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Rosuvastatin

Pharmacodynamic effects

Possible increased risk of HMG CoA inhibitor toxicity.

Increased risk of myopathy and rhabdomyolysis.

Recommendations

Contraindicated. Use alternative.

Alternative solution(s)

Monitor

Tests

Pharmacokinetic parameters
Parameters
Reference number
# patients
Dose
HCV
Frequency
AUC
Cmax
Sofosbuvir / Velpatasvir / Voxilaprevir
3379
19
400/100/200 mg
-
QD
 
 
Rosuvastatin
3379
19
10 mg
-
x 1
+ 639% (7.4x)
+ 1788% (18.9x)
Comment

Reference
  • 3379
    Sofosbuvir/Velpatasvir/Voxilaprevir (VOSEVI), Gilead, Ontario, Canada, 18 avril 2018.